Skip to main content
Addgene
Open Menu

pLenti-Cas9.mCherry
(Plasmid #208342)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 208342 Standard format: Plasmid sent in bacteria as agar stab 1 $89
Add to Cart

Backbone

  • Vector backbone
    pLenti-Cas9.mCherry
  • Total vector size (bp) 12770
  • Modifications to backbone
    Deleted U6 promoter and sgRNA sequence from LentiCRISPRv2-mCherry (Addgene 99154) leaving Cas9 and mCherry. Digested backbone with KpnI and EcoRI and replaced region using assembly cloning with the following oligo: gcagagatccagtttggttaattaaggtacaattcgctagctaggtcttgaaaggagtgg
  • Vector type
    Lentiviral, CRISPR

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert 1

  • Gene/Insert name
    Cas9
  • Alt name
    Csn1
  • Species
    S. pyogenes
  • Insert Size (bp)
    4104
  • GenBank ID
    69900935
  • Promoter EF-1a
  • Tag / Fusion Protein
    • nuclear localization sequence (NLS) and FLAG tag (C terminal on insert)

Cloning Information for Gene/Insert 1

Gene/Insert 2

  • Gene/Insert name
    mCherry
  • Species
    Synthetic
  • Insert Size (bp)
    708

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry

Trademarks:

  • Zeocin® is an InvivoGen trademark.

Depositor Comments

7.9kb LTR-to-LTR

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLenti-Cas9.mCherry was a gift from Peter S Nelson (Addgene plasmid # 208342 ; http://n2t.net/addgene:208342 ; RRID:Addgene_208342)

  • For your References section:

    Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies. Frank S, Persse T, Coleman I, Bankhead III A, Li D, De-Sarkar N, Wilson D, Rudoy D, Vashisth M, Galipeau P, Yang M, Hanratty B, Dumpit R, Morrissey C, Corey E, Montgomery RB, Haffner MC, Pritchard CC, Vasioukhin V, Ha G, Nelson PS. eLife 2025 10.7554/eLife.100081.2
Related items: